![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium‐derived vasoactive mediators is nitric oxide (NO), an endogenous messenger molecule formed in healthy vascular endothelium from the amino acid precursor L‐arginine. Endothelial dysfunction is caused by various cardiovascular risk factors, metabolic diseases, and systemic or local inflammation. One mechanism that explains the occurrence of endothelial dysfunction is the presence of elevated blood levels of asymmetric dimethylarginine (ADMA) – an L‐arginine analogue that inhibits NO formation and thereby can impair vascular function. Supplementation with L‐arginine has been shown to restore vascular function and to improve the clinical symptoms of various diseases associated with vascular dysfunction.
| Abbreviations | ||
| ACS | = | acute coronary syndrome |
| ADMA | = | asymmetric dimethylarginine |
| DDAH | = | dimethylarginine dimethylaminohydrolase |
| ICU | = | intensive care unit |
| L‐NMMA | = | NG‐monomethyl‐L‐arginine |
| NO | = | nitric oxide |
| PRMT | = | protein‐arginine methyltransferase |
| SDMA | = | symmetric dimethylarginine |
| Abbreviations | ||
| ACS | = | acute coronary syndrome |
| ADMA | = | asymmetric dimethylarginine |
| DDAH | = | dimethylarginine dimethylaminohydrolase |
| ICU | = | intensive care unit |
| L‐NMMA | = | NG‐monomethyl‐L‐arginine |
| NO | = | nitric oxide |
| PRMT | = | protein‐arginine methyltransferase |
| SDMA | = | symmetric dimethylarginine |